| Literature DB >> 21694881 |
Hare Krishna Tiwari1, Darshan Sapkota, Malaya Ranjan Sen.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is an important nosocomial and community pathogen. The objectives of this study were to estimate the prevalence of multidrug-resistant MRSA strains in clinical specimens and to investigate the sensitivity pattern of these strains against various antibiotics used for treating hospitalized and out patients. Strains were identified using standard procedures, and their sensitivity pattern was investigated using such techniques as disc diffusion, minimum inhibitory concentration (MIC), and the mecA gene PCR. Among 783 isolates of S. aureus, 301 (38.44%) were methicillin-resistant, of which 217 (72.1%) were found to be multidrug-resistant. Almost all MRSA strains were resistant to penicillin, 95.68% were resistant to cotrimoxazole, 92.36% were resistant to chloramphenicol, 90.7% were resistant to norfloxacin, 76.1% were resistant to tetracycline, and 75.75% were resistant to ciprofloxacin. Vancomycin was the most effective drug, with only 0.33% of MRSA strains being resistant to it. It is concluded that antibiotics other than vancomycin can be used as anti-MRSA agents after a sensitivity test so as to preclude the emergence of resistance to it and that prevailing problems in chemotherapy will escalate unless indiscriminate and irrational usage of antibiotics is checked.Entities:
Keywords: India; multidrug-resistant MRSA; prevalence
Year: 2008 PMID: 21694881 PMCID: PMC3108723 DOI: 10.2147/idr.s4105
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Resistance pattern of MRSA against various antimicrobials and its relative distribution in OPDs and wards
| Penicillin | 97% (292) | 96.79% (181) | 97.37% (111) |
| Gentamicin | 55.81% (168) | 55.6% (104) | 56.14% (64) |
| Tobramycin | 53.49% (161) | 54.01% (101) | 52.63% (60) |
| Amikacin | 41.53% (125) | 40.64% (76) | 42.98% (49) |
| Netilmicin | 65.78% (198) | 65.24% (122) | 66.67% (76) |
| Norfloxacin | 90.7% (273) | 90.91% (170) | 90.35% (103) |
| Ciprofloxacin | 75.75% (228) | 76.47% (143) | 75.56% (85) |
| Chloramphenicol | 92.36% (278) | 90.91% (170) | 94.74% (108) |
| Erythromycin | 68.77% (207) | 66.31% (124) | 72.81% (83) |
| Tetracycline | 76.1% (229) | 73.79% (138) | 79.82% (91) |
| Trimethoprim/Sulphamethoxazole | 95.68% (288) | 94.12% (176) | 98.25% (112) |
| Nitrofurantoin | 58.14% (175) | 60.43% (113) | 54.4% (62) |
| Vancomycin | 0.33% (1) | 0% | 0.88% (1) |
| Cefoperazone/Sulbactam | 65.12% (196) | 67.91% (127) | 60.53% (69) |
Note:
Test done only for urine isolates.
Abbreviations: MRSA, methicillin-resistant Staphylcoccus aureus; OPD, outpatient departments.
Multidrug resistance* in MRSA
| More than three nonvancomycin antimicrobials | 45.18% (136) |
| All antimicrobials except vancomycin | 22.25% (67) |
| All antimicrobials except vancomycin and cefoperazone/sulbactam | 4.31% (13) |
| All antimicrobials | 0.033% (1) |
| Total multidrug resistance | 72.1% (217) |
Note:
MRSA strains which were resistant to three or more than three antibiotics tested were considered to be multidrug-resistant MRSA.
Abbreviation: MRSA, methicillin-resistant Staphylcoccus aureus.
Frequency of S. aureus and MRSA in specimens
| Pus and wound specimens | 68.9% (540) | 42.2% (228) |
| Blood | 2.9% (23) | 34.8% (8) |
| Respiratory specimens | 3.3% (26) | 34.6% (9) |
| Mid stream | 20.0 % (157) | 26.7% (42) |
| Catheterized | 2.4% (19) | 63.1% (12) |
| Urine | ||
| Bone aspirate | 1.0% (8) | 12.5% (1) |
| CSF, ascetic fluid, EPF, HVS | 1.3% (10) | 10% (1) |
Abbreviations: CSF, cerebrospinal fluid; EPF, expressed prostatic fluid; HVS, high vaginal swab; MRSA, methicillin-resistant Staphylcoccus aureus.